|
Volumn 25, Issue 3, 2002, Pages 153-163
|
Cardiac and CNS toxicity of levobupivacaine strength of evidence for advantage over bupivacaine: Strength of evidence for advantage over bupivacaine
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BUPIVACAINE;
DEXBUPIVACAINE;
EPHEDRINE;
LEVOBUPIVACAINE;
LOCAL ANESTHETIC AGENT;
LONG ACTING DRUG;
OXYGEN;
POTASSIUM CHANNEL;
PROPOFOL;
SODIUM CHANNEL;
THIOPENTAL;
UNCLASSIFIED DRUG;
BLOOD PRESSURE REGULATION;
CARDIOTOXICITY;
CLINICAL TRIAL;
CONVULSION;
COST BENEFIT ANALYSIS;
DOG;
DRUG CHOICE;
DRUG COST;
DRUG MARKETING;
DRUG POTENCY;
DRUG RECEPTOR BINDING;
DRUG SAFETY;
DRUG WITHDRAWAL;
ELECTROCARDIOGRAM;
ELECTROENCEPHALOGRAM;
FOOD AND DRUG ADMINISTRATION;
HEART MUSCLE CONTRACTILE FORCE;
HEART VENTRICLE FIBRILLATION;
HEART VENTRICLE TACHYCARDIA;
HEMODYNAMIC MONITORING;
HUMAN;
LETHAL DOSE;
LOCAL ANESTHESIA;
NEUROTOXICITY;
NONHUMAN;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
QT INTERVAL;
REVIEW;
SHEEP;
TINNITUS;
VERTIGO;
|
EID: 0036251841
PISSN: 01145916
EISSN: None
Source Type: Journal
DOI: 10.2165/00002018-200225030-00002 Document Type: Review |
Times cited : (128)
|
References (41)
|